Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)
- Status
- UNKNOWN
- Phase
- PHASE2
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
- Status
- COMPLETED
- Phase
- PHASE1
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
WIRE - Novel Treatments in Renal Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2